Toyota To Launch All-new 2023 Toyota Sequoia In Late Summer 2022

Automaker Toyota Motor Corp. (TM) announced Wednesday it is set to unveil the all-new 2023 Toyota Sequoia that will live up to its powerful and legendary namesake, with a head-turning new look, luxurious comfort, impressive technology and the perfect blend of performance and efficiency.

Coupled with Toyota's long-lasting quality, durability and reliability, the three-row SUV will compete in the large-size SUV segment when it hits dealerships at the end of the summer 2022 with a Manufacturer's Suggested Retail Pricing (MSRP) starting at $58,300.

The third-generation Sequoia is completely redesigned and worthy of the "all-new SUV" description. All 2023 Sequoia will feature the powerful twin-turbo V6 hybrid i-FORCE MAX powertrain. First unveiled on Tundra, this exceptional hybrid produces 437 horsepower and 583 lb.-ft. of torque with a maximum towing capacity of up to 9,520 lbs., a 28 percent increase over the previous generation model.

The i-FORCE MAX is a cleverly engineered powertrain featuring a unique motor generator within the bell housing between the twin-turbo engine and the 10-speed automatic transmission.

The SUV will be assembled in the U.S. at Toyota Motor Manufacturing, Texas in San Antonio.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT